Results 171 to 180 of about 38,154 (222)

Clinical and Economic Consequences of a First Major Bleeding Event in Patients Treated with Direct Factor Xa Inhibitors in Spain: A Long-Term Observational Study. [PDF]

J Clin Med
Escobar C, Palacios B, Villarreal M, Gutiérrez M, Capel M, Aranda U, Hernández I, García M, Lledó L, Arenillas JF.   +9 more
europepmc   +1 more source

Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA-4: Time and Severity Matter Most. [PDF]

Stroke Vasc Interv Neurol
Concha M, Xu L, Horn M, Ohara T, Nakamya J, Beyer-Westendorf J, Shoamanesh A, Cohen A, Ladenvall P, Connolly SJ, Demchuk AM.   +10 more
europepmc   +1 more source

Clinical Characteristics and Incidence of Hemorrhagic Complications in Patients Taking Factor Xa Inhibitors in Spain: A Long-Term Observational Study. [PDF]

J Clin Med
Escobar C, Palacios B, Villarreal M, Gutiérrez M, Capel M, Hernández I, García M, Lledó L, Arenillas JF.   +8 more
europepmc   +1 more source

Factor Xa inhibitors versus low-molecular-weight heparin for preventing coagulopathy following COVID-19: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Amin L, Qayyum K, Uzair M, Khan F, Sethi P, Hanif L, Azhar A, Mazhar S, Ejaz U, Jawad S.   +9 more
europepmc   +1 more source

Factor Xa inhibitors versus warfarin in patients with non-valvular atrial fibrillation and diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Zahoor MM, Mazhar S, Azhar A, Mand Khan F, Anees U, Vohra RR, Ejaz U, Jawad S.   +7 more
europepmc   +1 more source

Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. [PDF]

Clin Pharmacokinet
Rohr BS, Krohmer E, Foerster KI, Burhenne J, Schulz M, Blank A, Mikus G, Haefeli WE.   +7 more
europepmc   +1 more source

Efficacy and safety of oral factor Xa inhibitors versus vitamin-K antagonists in the early phase after acute ischemic stroke or TIA in the real-world setting: The PRODAST study. [PDF]

Eur Stroke J
Diener HC, Grosse GM, Hüsing A, Stang A, Kuklik N, Brinkmann M, Maurer GD, Soda H, Pohlmann C, Hilker-Roggendorf R, Popovic N, Kraft P, Mackert BM, Eschenfelder CC, Weimar C.   +14 more
europepmc   +1 more source

Low-molecular-weight heparin is associated with lower venous thromboembolism events than factor Xa inhibitors in patients with severe blunt trauma: a cohort study from the Trauma Quality Improvement Program. [PDF]

Int J Surg
Chan SY, Huang JF, Cheng CT, Hsu CP, Liao CH, Fu CY.   +5 more
europepmc   +1 more source